Inno-Gene S.A. Stock price

Equities

IGN

PLINNGN00015

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.7 PLN +3.03% Intraday chart for Inno-Gene S.A. -5.56% -22.73%
Sales 2021 29.88M 7.48M Sales 2022 300K 75.07K Capitalization 35.12M 8.79M
Net income 2021 6M 1.5M Net income 2022 -1M -250K EV / Sales 2021 1.65 x
Net cash position 2021 5.4M 1.35M Net Debt 2022 3.98M 995K EV / Sales 2022 130 x
P/E ratio 2021
8.91 x
P/E ratio 2022
-17.6 x
Employees 10
Yield 2021 *
-
Yield 2022
-
Free-Float 58.81%
More Fundamentals * Assessed data
Dynamic Chart
Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Inno-Gene S.A. announced that it expects to receive PLN 1 million in funding CI
Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inno-Gene S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Inno-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Ignitis to Secure $119 Million Credit Line to Bolster Capital Amid Higher Energy Prices MT
Naturativ Sp. z o.o. announced that it has received PLN 0.49995 million in funding from Inno-Gene S.A. CI
Inno-Gene S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Inno-Gene S.A. acquired additional 10.72% minority stake in Naturativ for PLN 0.01 million. CI
Inno-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Ignitis Expects Debt Repayment, Compensation as Lithuania Enacts Anti-Inflation Measures MT
More news
1 day+3.03%
1 week-5.56%
Current month-29.75%
1 month-29.17%
3 months-21.66%
6 months-54.18%
Current year-22.73%
More quotes
1 week
1.65
Extreme 1.65
1.70
1 month
1.65
Extreme 1.65
2.53
Current year
1.65
Extreme 1.65
3.01
1 year
1.65
Extreme 1.65
6.10
3 years
1.65
Extreme 1.65
18.90
5 years
1.45
Extreme 1.45
98.80
10 years
0.88
Extreme 0.88
98.80
More quotes
Managers TitleAgeSince
Chief Executive Officer - 10-05-31
Members of the board TitleAgeSince
Director/Board Member - -
Chairman - 15-12-31
Director/Board Member - -
More insiders
Date Price Change Volume
24-03-28 1.7 +3.03% 2,658
24-03-27 1.65 -2.37% 4,602
24-03-26 1.69 -0.59% 9,816
24-03-25 1.7 -6.59% 7,020
24-03-22 1.82 +1.11% 1,653

End-of-day quote Warsaw S.E., March 27, 2024

More quotes
Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA's portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
More about the company
  1. Stock
  2. Equities
  3. Stock Inno-Gene S.A. - Warsaw S.E.